| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-Bacterial Agents | 21 | 2019 | 10083 | 1.29 | Why? |
| Bacterial Infections | 4 | 2018 | 2229 | 1.07 | Why? |
| Bacteremia | 11 | 2019 | 1372 | 1.00 | Why? |
| Meningitis, Pneumococcal | 1 | 2021 | 35 | 0.88 | Why? |
| Drug Resistance, Multiple, Bacterial | 3 | 2018 | 1115 | 0.87 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 66 | 0.85 | Why? |
| Neutropenia | 3 | 2018 | 388 | 0.83 | Why? |
| Fluoroquinolones | 2 | 2018 | 235 | 0.80 | Why? |
| Escherichia coli Proteins | 2 | 2019 | 168 | 0.80 | Why? |
| Tuberculosis, Meningeal | 1 | 2021 | 100 | 0.78 | Why? |
| Antimicrobial Stewardship | 5 | 2019 | 931 | 0.65 | Why? |
| Escherichia coli | 4 | 2019 | 1547 | 0.62 | Why? |
| Arginine | 1 | 2019 | 377 | 0.61 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.58 | Why? |
| Staphylococcal Infections | 8 | 2018 | 1099 | 0.57 | Why? |
| Medical Overuse | 1 | 2017 | 146 | 0.55 | Why? |
| Carrier Proteins | 1 | 2017 | 513 | 0.53 | Why? |
| Drug Prescriptions | 3 | 2019 | 1062 | 0.49 | Why? |
| Germany | 22 | 2021 | 9196 | 0.47 | Why? |
| Staphylococcus aureus | 5 | 2018 | 844 | 0.46 | Why? |
| Cephalosporins | 3 | 2018 | 250 | 0.44 | Why? |
| Hospital Administration | 1 | 2017 | 650 | 0.41 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.37 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2011 | 167 | 0.36 | Why? |
| Hematologic Neoplasms | 2 | 2020 | 2105 | 0.36 | Why? |
| Microbial Sensitivity Tests | 6 | 2019 | 2886 | 0.35 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.34 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.33 | Why? |
| Abscess | 2 | 2018 | 234 | 0.29 | Why? |
| Infectious Disease Medicine | 2 | 2018 | 311 | 0.29 | Why? |
| Antitubercular Agents | 1 | 2011 | 775 | 0.27 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.26 | Why? |
| Hospitals, University | 4 | 2020 | 4173 | 0.25 | Why? |
| Spirochaetales Infections | 1 | 2021 | 10 | 0.23 | Why? |
| Klebsiella | 2 | 2018 | 35 | 0.22 | Why? |
| Ticks | 2 | 2018 | 107 | 0.22 | Why? |
| Brain Abscess | 1 | 2021 | 50 | 0.22 | Why? |
| Tuberculosis, Pulmonary | 1 | 2011 | 1171 | 0.21 | Why? |
| Churg-Strauss Syndrome | 1 | 2020 | 61 | 0.20 | Why? |
| Aldosterone | 1 | 2021 | 155 | 0.20 | Why? |
| Multidrug Resistance-Associated Proteins | 1 | 2019 | 29 | 0.19 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.19 | Why? |
| Relapsing Fever | 1 | 2018 | 14 | 0.19 | Why? |
| Acyltransferases | 1 | 2019 | 61 | 0.19 | Why? |
| Borrelia | 1 | 2018 | 39 | 0.19 | Why? |
| Brucella melitensis | 1 | 2018 | 10 | 0.19 | Why? |
| Naturopathy | 1 | 2018 | 11 | 0.18 | Why? |
| Immune Reconstitution | 1 | 2018 | 48 | 0.18 | Why? |
| Anti-Infective Agents | 3 | 2018 | 1766 | 0.18 | Why? |
| Cyclophosphamide | 1 | 2020 | 387 | 0.18 | Why? |
| Potassium | 1 | 2021 | 325 | 0.18 | Why? |
| Biological Transport, Active | 1 | 2017 | 46 | 0.18 | Why? |
| Granulomatosis with Polyangiitis | 1 | 2020 | 161 | 0.18 | Why? |
| Francisella tularensis | 1 | 2017 | 28 | 0.18 | Why? |
| Ancylostomiasis | 1 | 2017 | 3 | 0.18 | Why? |
| Schistosomiasis | 1 | 2018 | 59 | 0.18 | Why? |
| Enterobacter | 1 | 2017 | 18 | 0.18 | Why? |
| Ancylostoma | 1 | 2017 | 4 | 0.18 | Why? |
| Encephalitis Viruses, Tick-Borne | 1 | 2018 | 100 | 0.17 | Why? |
| Chemotherapy, Adjuvant | 1 | 2021 | 606 | 0.17 | Why? |
| Tularemia | 1 | 2017 | 25 | 0.17 | Why? |
| HIV Infections | 2 | 2021 | 11620 | 0.17 | Why? |
| Brucellosis | 1 | 2018 | 49 | 0.17 | Why? |
| Encephalitis, Tick-Borne | 1 | 2018 | 86 | 0.17 | Why? |
| Disk Diffusion Antimicrobial Tests | 1 | 2016 | 36 | 0.17 | Why? |
| Specialization | 2 | 2018 | 432 | 0.17 | Why? |
| Oncology Service, Hospital | 1 | 2020 | 314 | 0.16 | Why? |
| Drug Utilization | 2 | 2017 | 619 | 0.16 | Why? |
| Retinitis | 1 | 2017 | 42 | 0.16 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.16 | Why? |
| Soft Tissue Infections | 1 | 2018 | 116 | 0.16 | Why? |
| Mutagenesis | 1 | 2019 | 394 | 0.16 | Why? |
| Tick-Borne Diseases | 1 | 2017 | 68 | 0.16 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.16 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.16 | Why? |
| Rifampin | 1 | 2018 | 276 | 0.16 | Why? |
| Shock, Septic | 3 | 2021 | 1313 | 0.15 | Why? |
| Febrile Neutropenia | 1 | 2018 | 179 | 0.15 | Why? |
| Skin | 2 | 2018 | 2096 | 0.15 | Why? |
| Gene Deletion | 1 | 2017 | 430 | 0.15 | Why? |
| Enterobacteriaceae Infections | 2 | 2018 | 529 | 0.15 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.14 | Why? |
| Unnecessary Procedures | 1 | 2017 | 175 | 0.14 | Why? |
| Angiotensin II | 1 | 2021 | 601 | 0.14 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.14 | Why? |
| Ofloxacin | 1 | 1994 | 23 | 0.14 | Why? |
| Early Medical Intervention | 1 | 2018 | 487 | 0.14 | Why? |
| Quality Indicators, Health Care | 1 | 2019 | 580 | 0.14 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.14 | Why? |
| Lipopolysaccharides | 1 | 2019 | 848 | 0.14 | Why? |
| Vancomycin | 1 | 2016 | 328 | 0.13 | Why? |
| Humans | 52 | 2021 | 930598 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.12 | Why? |
| Up-Regulation | 1 | 2021 | 2249 | 0.12 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Drug Resistance, Bacterial | 2 | 2017 | 1414 | 0.12 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.12 | Why? |
| Sepsis | 2 | 2021 | 3517 | 0.12 | Why? |
| Internal Medicine | 1 | 2018 | 557 | 0.12 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| Tuberculin Test | 1 | 2011 | 141 | 0.10 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.10 | Why? |
| Escherichia coli Infections | 1 | 1994 | 348 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.09 | Why? |
| Leukemia | 1 | 1994 | 598 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Aged | 22 | 2021 | 215776 | 0.09 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.09 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2011 | 260 | 0.09 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.09 | Why? |
| Guideline Adherence | 2 | 2018 | 2309 | 0.09 | Why? |
| Male | 29 | 2021 | 367725 | 0.09 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.09 | Why? |
| Latent Tuberculosis | 1 | 2011 | 324 | 0.08 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
| Female | 27 | 2021 | 380317 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Fever | 2 | 2018 | 7795 | 0.08 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.08 | Why? |
| Inpatients | 2 | 2019 | 5161 | 0.07 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2011 | 433 | 0.07 | Why? |
| Travel | 3 | 2018 | 7220 | 0.07 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.07 | Why? |
| Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.07 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.07 | Why? |
| Point-of-Care Testing | 1 | 2018 | 2782 | 0.07 | Why? |
| Tuberculosis | 1 | 2021 | 2895 | 0.07 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.07 | Why? |
| Opportunistic Infections | 1 | 2011 | 602 | 0.07 | Why? |
| Poverty | 2 | 2018 | 2302 | 0.07 | Why? |
| Adult | 17 | 2021 | 244371 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.06 | Why? |
| Europe | 2 | 2018 | 12702 | 0.06 | Why? |
| Multicenter Studies as Topic | 2 | 2021 | 2437 | 0.06 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.06 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.06 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.06 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Africa South of the Sahara | 2 | 2018 | 1335 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Mesylates | 1 | 2021 | 33 | 0.06 | Why? |
| Cross Infection | 3 | 2020 | 8675 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Drug Resistance, Microbial | 2 | 2018 | 419 | 0.06 | Why? |
| Empiricism | 1 | 2000 | 3 | 0.06 | Why? |
| Physicians | 2 | 2018 | 4214 | 0.06 | Why? |
| Pneumonia | 2 | 2018 | 5652 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Interferon-gamma | 1 | 2011 | 2711 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.05 | Why? |
| Child | 6 | 2021 | 70012 | 0.05 | Why? |
| Ambulatory Care | 1 | 2018 | 4947 | 0.05 | Why? |
| European Union | 1 | 2004 | 565 | 0.05 | Why? |
| Nymph | 1 | 2018 | 11 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Esters | 1 | 2021 | 300 | 0.05 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.05 | Why? |
| Staphylococcal Skin Infections | 1 | 2018 | 32 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Ixodes | 1 | 2018 | 58 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Cephalosporin Resistance | 1 | 2017 | 12 | 0.04 | Why? |
| Genes, Helminth | 1 | 2017 | 1 | 0.04 | Why? |
| Palliative Medicine | 1 | 2018 | 46 | 0.04 | Why? |
| Minisatellite Repeats | 1 | 2017 | 53 | 0.04 | Why? |
| Tanzania | 1 | 2018 | 294 | 0.04 | Why? |
| DNA, Helminth | 1 | 2017 | 15 | 0.04 | Why? |
| Ophthalmoscopes | 1 | 2017 | 6 | 0.04 | Why? |
| Tetracycline | 1 | 2017 | 33 | 0.04 | Why? |
| Theranostic Nanomedicine | 1 | 2018 | 143 | 0.04 | Why? |
| Antibodies, Helminth | 1 | 2017 | 48 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2021 | 450 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Fungemia | 1 | 2018 | 86 | 0.04 | Why? |
| Drug Utilization Review | 1 | 2017 | 72 | 0.04 | Why? |
| Prednisolone | 1 | 2020 | 443 | 0.04 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.04 | Why? |
| Vancomycin Resistance | 1 | 2016 | 55 | 0.04 | Why? |
| Cross-Sectional Studies | 6 | 2021 | 53120 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2021 | 7268 | 0.04 | Why? |
| Guanidines | 1 | 2021 | 499 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Osteomyelitis | 1 | 2018 | 131 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Candida albicans | 1 | 2018 | 217 | 0.04 | Why? |
| Tertiary Healthcare | 1 | 2020 | 616 | 0.04 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.04 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.04 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.04 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.04 | Why? |
| Doxycycline | 1 | 2018 | 307 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Phylogeny | 3 | 2018 | 13341 | 0.04 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.03 | Why? |
| Creatinine | 1 | 2021 | 1443 | 0.03 | Why? |
| Principal Component Analysis | 1 | 2017 | 689 | 0.03 | Why? |
| Osteoarthritis | 1 | 2017 | 205 | 0.03 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.03 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.03 | Why? |
| Candidiasis | 1 | 2018 | 334 | 0.03 | Why? |
| Benchmarking | 1 | 2017 | 627 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2018 | 1517 | 0.03 | Why? |
| Catheterization, Central Venous | 1 | 2018 | 458 | 0.03 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.03 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.03 | Why? |
| Models, Statistical | 2 | 2020 | 5312 | 0.03 | Why? |
| Phylogeography | 1 | 2017 | 824 | 0.03 | Why? |
| Rituximab | 1 | 2020 | 1096 | 0.03 | Why? |
| France | 2 | 2018 | 12074 | 0.03 | Why? |
| Neoplasms | 1 | 2020 | 17251 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.03 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.03 | Why? |
| Asia | 1 | 2018 | 2399 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.03 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.03 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.03 | Why? |
| Smell | 1 | 2020 | 1851 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.03 | Why? |
| Animals | 4 | 2018 | 78931 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.03 | Why? |
| Taste Disorders | 1 | 2021 | 1720 | 0.02 | Why? |
| Recovery of Function | 1 | 2020 | 2461 | 0.02 | Why? |
| United States | 1 | 2017 | 46150 | 0.02 | Why? |
| Sputum | 1 | 2018 | 1720 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.02 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 1692 | 0.02 | Why? |
| Double-Blind Method | 1 | 2020 | 5988 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| South Africa | 1 | 2018 | 3326 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2016 | 1318 | 0.02 | Why? |
| Quality of Health Care | 1 | 2019 | 1948 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.02 | Why? |
| Parents | 1 | 2021 | 2758 | 0.02 | Why? |
| Administration, Oral | 1 | 1994 | 2340 | 0.02 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.02 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.02 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Genotype | 1 | 2016 | 4697 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Infant | 2 | 2018 | 30274 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.02 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.02 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.02 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2016 | 6543 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Education, Medical, Graduate | 1 | 2018 | 2082 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Communicable Diseases, Emerging | 1 | 2018 | 2523 | 0.02 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.02 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.02 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Acute Disease | 1 | 1994 | 6029 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2018 | 29620 | 0.01 | Why? |